ABOUT SHSA 2020

Join us for the 5th Annual Symposium on Hidradenitis Suppurativa Advances – online! Due to the ongoing restrictions of Covid19, the 5th SHSA will be held virtually, to allow for maximum participation and to provide learning opportunities for physicians, AHW. medical students and a patients.

Symposium on Hidradenitis Suppurativa Advances (SHSA)  provides an interdisciplinary forum for leading academic scientists, clinicians and researchers to share their experiences, discuss innovations and research regarding Hidradenitis Suppurativa (HS)​. Patients and caregivers are encouraged to learn from the science presented. Support chat groups are planned for this virtual format. 

The 5th SHSA will include interactive educational sessions, including two live 110-120 minute sessions each day on October 10 and 11. Included in this online format:

  • Live presentations and Q&A and Panel Sessions
  • Pre-recorded presentations
  • Abstracts
  • Virtual Exhibit Hall – meet with suppliers who will showcase products and technology focused on treatment of HS.
  • Poster Viewing – view posters and interact with authors of the most current research on HS
  • Chat rooms for support groups and specializations

Highlights:

  • Current research ranging from the burden of disease to new treatment modalities
  • Latest innovations and clinical challenges in HS
  • Raise your awareness of HS and unmet needs of patients

Hosted by:

Iltefat Hamzavi, MD, FAAD                            
President, HSF

 

 


IMPORTANT DATES

Call for Abstracts opens February 2020
Online registration opens February 2020
Abstract submission deadline July 3, 2020
Notice of Abstract adjudication July 24, 2020
2nd Call for Abstracts/Late-breaking opens Monday July 27, 2020
2nd Call for Abstracts deadline August 14, 2020
Deadline for presenting authors to register August 28, 2020
Online registration closes September 30, 2020

CONFERENCE CO-CHAIRS

Isabelle Delorme, MD, President, Canadian Hidradenitis Suppurativa Foundation and Dermatologist, Dr. Isabelle Delorme Inc., Drummondville, QC, Canada

Joslyn Sciacca Kirby, MD, Assoc. Professor and Vice Chair of Education, Depart. of Dermatology, Pennsylvania State, Hershey, PA, USA

COMMITTEE MEMBERS

Afsaneh AlaviMD, MSc, FRCPC, Professor, Dermatology, University of Toronto and Women’s College Hospital, Toronto, ON, Canada

Raed AlhusayenMBBS, MSCE, FRCPC, Assoc. Professor, University of Toronto, Assoc. Scientist, Sunnybrook Research Institute, Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Marc Bourcier, MD, FRCPS, Dermatologist, Durondel CP, Moncton, NB, Canada

Angel Byrd, MD, PhD, Asst. Professor | Adjunct Asst. Professor, Dermatology, Howard University College of Medicine | Johns Hopkins University School of Medicine, Washington, DC, USA

Steven Daveluy, MD, FAAD, Assoc. Professor and Program Director, Dermatology, Wayne State University, Detroit, MI, USA

Ralph George, MD, FRCS, Assoc. Professor, General Surgery, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada

Stephanie Goldberg, MD, Assoc. Professor of Surgery, Medical Director VCU ACCESS, Virginia Commonwealth University School of Medicine, Richmond, VA, USA

Sandra Guilbault, Director, Community Lead, Hope for HS, Detroit, MI, USA

Iltefat Hamzavi, MD, FAAD, President HSF | Dermatologist, Dept. of Dermatology, Henry Ford Hospital, Detroit, MI, USA

Paul Hazen, MD, Case-Western Reserve University School of Medicine, Clinical Associate Professor of Dermatology, Ohio University College of Osteopathic Medicine, Director, Division of Dermatology, Fairview General Hospital, Loraine, OH, USA

Hadar Lev-Tov, MD, MAS, Asst. Professor, Dr. Philip Frost Department of Dermatology and Cutaneous Surgery,  University of Miami, Miller School of Medicine, Miami, FL, USA

Michelle LowesMB.BS, PhDPhysician, The Rockefeller University, New York, NY, USA

Angela Miller, Clinical Research Manager, Dermatology, Henry Ford Health Systems and National Director,Hope for HS, Detroit, MI

Elizabeth O’Brien, MD, Assoc. Professor, Internal Medicine, McGill University Health Centre, Montreal, QC, Canada

Vincent Piguet, MD, PhD, FRCP, Dept. Division Director Dermatology, Professor Dept. of Medicine| Division Head Dermatology, University of Toronto | Women’s College Hospital, Toronto, ON, Canada

Se Mang (Simon) Wong, MD, FRCPC, Clinical Assoc. Professor, UBC Department of Dermatology and Skin Science, Vancouver, BC, Canada

ACCREDITATION:

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Dermatology Association.

You may claim a maximum of 7.5 hours (credits are automatically calculated).

 

AMA  (Agreement dates: January 1, 2017 to December 31, 2020)

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Visit the AMA website for more information on the process to convert Royal College MOC credit to AMA credit.

EUMS  (Agreement dates: December 20, 2016 to December 31, 2020)

Live educational activities recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists (UEMS) eligible for ECMEC®.

QCHP  (Agreement dates: January 1, 2017 to December 31, 2021)

 Through an agreement between the Royal College of Physicians and Surgeons of Canada and the Qatar Council for Healthcare Practitioners, healthcare practitioners participating in the QCHP CME/CPD program may record MOC Section 1 or MOC Section 3 credits as QCHP Category 1 or Category 3 credits.

PROGRAM

Download the Program at a Glance or expand the days below for the program details.  Please note, sessions will be recorded and available on the SHSA Virtual Platform for viewing by registered attendees for up to a year following the conference.

The Program and Abstract Book can now be downloaded HERE.

 

Select a day and session to expand the program details below:

PROGRAM

SPEAKERS

The SHSA Committee have ensured the program features the most highly-regarded speakers in the field of HS, rising stars and HS researchers.  These speakers are leading efforts to treat HS in the best possible way, and spearheading HS research.

REGISTRATION FOR VIRTUAL CONFERENCE

Registration for the 5th SHSA is now closed.

All registered attendees were emailed a link from the SHSA App that will enable you to log onto the conference platform. We recommend you bookmark this link for easy access to the SHSA App. Go to: https://5th-annual-symposium.pathable.co/

Please note, sessions will be recorded and available on the SHSA Virtual Platform for viewing by registered attendees for up to a year following the conference.

Physician, Nurse/Allied Health, Resident/Fellow, Medical Students and Patients/Caregivers have full access to all virtual SHSA activities, including:

  • Live presentations and Q&A and Panel Sessions
  • Pre-recorded presentations
  • Abstracts
  • Virtual Exhibit Hall – meet with suppliers who will showcase products and technology focused on treatment of HS.
  • Poster Viewing – view posters and interact with authors of the most current research on HS
  • Chat rooms for support groups and specializations

Registration fees are in $ CAD; Ontario taxes (13% HST) will be applicable to registration fees shown below.  Online registration is now open.

 

CONFERENCE Cost
Physician (Dermatologist or other specialist)        ​
$200
Nurse or Allied Health Worker*
$200
Resident* or Fellow*
$100
Medical Student*
$75
Patient / Caregiver**
$50
Industry Sponsor***
$300
Non-sponsoring Industry
$1000

 

Online registration will close at midnight PST on Wednesday, September 30, 2020. Login instructions for the virtual conference platforms will be sent to all registered attendees by email one week prior to the conference.

*If you are a Resident, Fellow, Nurse, Allied Worker or Medical Student in training, your registration can only be confirmed upon receipt of written verification of your status by the chairman of your department or program director. Residents, Fellows and Medical Students must be in full-time enrollment in the current academic year. Please upload your verification letter/status when registering online.
**Patient/caregiver: limited number of registrants permitted on first-registered basis. See below for further information in Registration Terms.
***Industry Sponsors – a number of complimentary registrations are provided to sponsors, depending on sponsor level. A discount code will be provided to the main sponsor contact for distribution to the sponsor reps.

Payment can be made online by Credit Card (Visa or MasterCard) via the Conference Secretariat’s secure merchant account. If you are unable to register online, request a Registration Form from the Conference Secretariat at shsa@simplyeventful.com.

All registrants to the 5th SHSA must read and agree to the Registration Terms & Cancellation Policy in order to confirm your registration.

REGISTRATION TERMS & CANCELLATION POLICY

REGISTRATION TERMS FOR PATIENT / CAREGIVER CATEGORY
As the SHSA is intended to educate medical and scientific professionals who treat HS patients and have advanced medical knowledge, patients/caregivers agree that the information presented may be disturbing and will be presented at a high level of learning.

In order to confirm registration in this category, Patients / Caregivers must agree to the following terms:

  • Speakers cannot answer individual health questions in the scientific sessions or during breaks. Please see your own doctor after the conference if you have any treatment-related questions.
  • Please understand there may be images of advanced HS skin lesions or even videos of surgery.
  • Talks are directed at a medical and scientific audience. This means the language may feel impersonal. It does not reflect on the compassion of the speakers who are committed to studying HS and/or treating people with HS.

REGISTRATION CANCELLATION POLICY

Registration fees will be refunded upon written request to the Conference Secretariat by the following terms:

  • A 50% refund (plus tax) will apply for written cancellations received on or prior to September 18, 2020.
  • No refunds will apply for cancellations received on or after September 19, 2020.
  • Telephone cancellations will not be accepted.

Submit cancellation letters to the Conference Secretariat by e-mail (shsa@simplyeventful.com) or fax (604-738-8697).

BOOKING CONDITIONS & LIABILITY

The Canadian Hidradenitis Suppurativa Foundation (CHSF) and its appointed suppliers act as agents for, and make arrangements with companies providing services. Although great care is taken to choose suppliers, we are unable to control them directly and, therefore, cannot be responsible for their acts or omissions. A failure to supply the activity or service or a deficiency in same or damages which may arise during such activity are not the responsibility of the CHSF and its appointed suppliers and the submission of a registration form is based on this limitation. The CHSF, its employees, officers, volunteers, directors, contracted staff, contracted companies and agents cannot assume responsibility for any claims, losses, damages, costs or expense arising out of injury, accident or death, loss or damage to property, delay or inconvenience arising from any matters referred to herein.

CONDITIONS OF REGISTRATION

  1. It is agreed that the CHSF, its employees, officers, volunteers, directors, contracted staff, contracted companies and agents shall not be held liable or responsible for any loss or damages, however caused by any person engaged by, participating in, or attending the Symposium on Hidradenitis Suppurativa Advances 2020 for any reason, no matter howsoever caused.
  2. It is agreed that the CHSF, its employees, agents, volunteers, directors and officers reserve the right to refuse admission, cancel or reschedule programs, change speakers or location, or revise content at any time. Decisions regarding the necessity for such decisions shall be taken by the CHSF or its agents at their sole discretion and shall be final.
  3. It is agreed that those people who are not eligible to register under one of the categories set out in the conference registration brochure will not be permitted to register onsite and will not be allowed to attend any event taking place within the context of the Symposium on Hidradenitis Suppurativa Advances. In such instance, no registration fees, travel, accommodation, per diem or other expenses will be reimbursed by the CHSF or its agents.

ONLINE SUBMISSION is now closed

A second Call for Abstracts for new and late-breaking submissions was opened at the end of July. Deadline for the 2nd Call for Abstracts was August 14, 2020. Thank you for your submissions. 

View the instructions below or download the PDF.  Submissions will only be accepted online. 
Call for Abstracts and online registration opens​​
February 2020
Abstract submission deadline
 July 3, 2020
Notice of Abstract adjudication
July 24, 2020
2nd Call for Abstracts/Late-breaking opens
July 27, 2020
Deadline for 2nd Call for Abstract submissions
August 14, 2020
Deadline for presenting authors to register
August 28, 2020
Online registration closes September 30, 2020

Abstract Format

Please indicate your preference for oral or poster presentation in the online submission. Due to the limited number of oral presentations available in the SHSA program, meritorious abstracts not assigned to oral presentation, will be accepted for posters. Abstracts submitted by commercial industry representatives may only be considered for poster presentation. Indicate in the online submission system if you do not wish to accept a poster presentation in this instance, in which case your abstract may be declined should it not be accepted for oral presentation.As the 5th SHSA Conference is now a virtual event, travel and educational grants will not be distributed.

An acknowledgement of your abstract submission(s) will be sent via email to the corresponding author.

Abstracts will be peer reviewed, following the submission deadline on Friday, July 3.  Notifications will be sent to the accepted abstract submitters and accepted presenters by July 24th.   

2nd Call for Abstracts: Abstracts will be peer reviewed, following the submission deadline on Friday, August 14. This submission deadline will not be extended. Notifications will be sent to the accepted abstract submitters and accepted presenters by the end of August.    

Abstracts should present new information, and not have been submitted or published elsewhere (at the time of submission). When submitting an abstract, please select the topic that best applies to your abstract. Topics can be selected from the drop-down menu in the online submission system. Abstracts submitted by industry representatives may only be considered for poster presentation. Submitting authors and/or presenters may modify their submission(s) until the closing date.

Topics

Please submit your abstract by selecting one category out of the following that best describes its scientific content. Topics will be available in a drop-down menu on the online submission site. Categories will be used for reviewing and indexing purposes.

  • Epidemiology and Health Services Research
  • Clinical Research
  • Comorbidities and complications
  • Basic & Translational research
  • Therapy including surgical, medical, and complementary

Disclosure of Conflict

Authors are required to complete a Disclosure of Conflict form as part of the abstract submission. These will be included in the Final Program. Abstracts must be free of commercial bias and should only identify drug products by their generic names.

Condition of Acceptance

A condition of acceptance is that you must register for the conference no later than August 28, 2020 in order for the abstract to be included in the program.

Abstract Guidelines

  • Prepare your abstract in MS Word
  • Do not use presentation software, such as PowerPoint
  • Limit your abstract (body) to no more than 300 words
  • Refer to generic names, rather than brand names
  • It is suggested, other than case presentations, to separate your abstract into three (3) paragraphs:
    • Introduction
    • Methods, Results
    • Conclusions
  • Include learning objectives and a takeaway message.

Abstracts selected for presentations in the 5th Annual SHSA will be reproduced exactly as submitted and substitutions and changes will not be permitted after the closing date. Be sure to proofread your abstract very carefully before submitting. 

Sponsors   

For sponsorship information of the 5th SHSA, please contact Annette McCunn at shsa@simplyeventful.com or call 604-738-8600. 

The 5th SHSA 2020 gratefully acknowledges the support of the following Sponsors:

PLATINUM SPONSOR: 

AbbVie 

GOLD SPONSORS:
Appulse Medical
Incyte
Janssen
Pfizer

SILVER SPONSORS:

Chemocentryx
Novartis Pharmaceuticals Canada

UCB Biopharma

BRONZE SPONSOR:

HidraMed Solutions

 

Profound thanks to Dr. Ricardo Cibotti and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) for their support of the SHSA meeting and HS research.

Funding for this conference was made possible in part by R13AR077976 from NIAMS. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

To learn more about the 5th Annual SHSA or future SHSA meetings, please contact the Conference Secretariat for the Sponsorship Prospectus:

Annette McCunn
5th SHSA Conference Manager
c/o Simply Eventful Management Inc.
E: shsa@simplyeventful.com
T: 604-738-8600

More info    

           

Final Program and Abstracts from previous conferences are available for download: